Develops therapies for eye diseases, focusing on vascular endothelial growth factor inhibitors for retinal diseases.
Opthea Limited is a clinical stage biopharmaceutical company headquartered in South Yarra, Australia, specializing in the development and commercialization of innovative therapies primarily targeting eye diseases. Established in 1984, Opthea has built a robust intellectual property portfolio focused on Vascular Endothelial Growth Factors (VEGF) including VEGF-C, VEGF-D, and VEGF Receptor-3. These therapies are designed to address diseases characterized by abnormal blood and lymphatic vessel growth, as well as vascular leakage.
The company's flagship product, OPT 302, represents a soluble form of VEGFR 3 currently undergoing clinical development. OPT 302 shows promise as a novel treatment for wet neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Opthea is also advancing a pioneering class of VEGF-C/D inhibitors aimed at complementing existing VEGF-A inhibitors in the treatment of wet AMD and other retinal conditions. This strategic approach underscores Opthea's commitment to expanding therapeutic options and improving outcomes for patients suffering from debilitating eye disorders.
Formerly known as Circadian Technologies Limited, Opthea Limited underwent a rebranding in December 2015 to better reflect its evolving focus and vision within the biopharmaceutical sector. With a dedicated team of researchers and clinicians, Opthea continues to drive innovation in ophthalmic therapies, aiming to address unmet medical needs and enhance quality of life for individuals worldwide affected by severe eye diseases.